Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.

Cancer research - 1 Sept 1991

Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley F D, Zwelling L A

Abstract excerpt

HL-60/AMSA is a human leukemia cell line that is 50- to 100-fold more resistant to the cytotoxic actions of the topoisomerase II-reactive intercalator amsacrine than is its drug-sensitive HL-60 parent line. Previously, we have shown that the topoisomerase II from HL-60/AMSA is also resistant to inhibition by amsacrine and other intercalating agents. We therefore sought the molecular basis for the resistance of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Sequence
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Molecular Sequence Data

Share to Mutation

Share to Polymerase Chain Reaction

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 1651812

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.PMID 1651812Read ↗

Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.Semantic proximity Read ↗

A restriction fragment length polymorphism for human topoisomerase II: possible relationship to drug-resistance.Semantic proximity Read ↗

Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.Semantic proximity Read ↗

DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.Semantic proximity Read ↗

Megabase pair deletions in mutant mammalian cells following exposure to amsacrine, an inhibitor of DNA topoisomerase II.Semantic proximity Read ↗

Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.Semantic proximity Read ↗

Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. Implications in resistance to multiple antitumor drugs targeting the enzyme.Semantic proximity Read ↗

Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.Semantic proximity Read ↗

Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.Semantic proximity Read ↗

Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs.Semantic proximity Read ↗

Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.Semantic proximity Read ↗

Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell linesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.